Bismarck News Updates

Nonalcoholic Steatohepatitis (NASH) Market: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight

 Breaking News
  • No posts were found

Nonalcoholic Steatohepatitis (NASH) Market: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight

October 10
15:24 2021
Nonalcoholic Steatohepatitis (NASH) Market: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight
Nonalcoholic Steatohepatitis (NASH) Market

Nonalcoholic Steatohepatitis (NASH) is the progressive form of liver injury that carries a risk of progressive fibrosis, cirrhosis, and end-stage liver disease. It is an advanced form of nonalcoholic fatty liver disease (NAFLD), caused by the buildup of fat in the liver. When this buildup causes inflammation and damage, it is known as NASH, which can lead to scarring of the liver. Scarring of the liver is a potentially life-threatening condition called cirrhosis. NASH usually comes under the category of silent diseases that has very few or no symptoms typically because it does not cause any symptoms until it is too late. In the early period, patients did not complain about anything specific. Even with the advancing fibrosis, the disease may not have any specific problems. However, in the later stages, patients may start developing some non-specific symptoms.

 

DelveInsight’s “Nonalcoholic Steatohepatitis (NASH) Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Nonalcoholic Steatohepatitis (NASH), historical and forecasted epidemiology as well as the Nonalcoholic Steatohepatitis (NASH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of Nonalcoholic Steatohepatitis (NASH) Market are:

  • Of all the prevalent cases of NAFLD in the 7MM, approximately 19% of the population fulfilled the criteria for NASH. These cases are expected to increase throughout the study period [2018–2030].
  • We estimate the highest prevalence of NASH in the United States, accounting close to 50% of the total prevalent cases, followed by Japan.
  • On the other hand, it is assessed that among the European countries, Germany accounted for the highest prevalent population, followed by Italy. Among all the 7MM countries, Spain had the lowest prevalent population.
  • Namodenoson (CF102) by Can-Fite BioPharma, Belapectin (GR-MD-02) by Galectin Therapeutics, and Immuron’s IMM-124E is expected to enter the NASH therapeutics market.

 

Request for Sample Report: https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market

 

Scope of the Nonalcoholic Steatohepatitis (NASH) Market Report

  • The report covers the descriptive overview of Nonalcoholic Steatohepatitis (NASH), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Nonalcoholic Steatohepatitis (NASH) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Nonalcoholic Steatohepatitis (NASH) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Nonalcoholic Steatohepatitis (NASH) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Nonalcoholic Steatohepatitis (NASH) market

The classification of fibrosis stages of NASH is as follows: No Fibrosis (F0), NASH Fibrosis (F1–F3), and NASH Cirrhosis (F4). According to various studies, such as Schuppan et al. (2018), Singh et al. (2014), and others, NASH has been defined to keep progressing from early stages (F0 and F1) to advanced stages (F2–F4) over time. The development of NASH with cirrhosis increases the risk of NASH Decompensated Cirrhosis and ultimately to death.

 

Request for Sample Report: https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market

 

Some of Nonalcoholic Steatohepatitis (NASH) Companies are:

  • Ascletis Pharma
  • Bristol-Myers Squibb (BMS)
  • Can-Fite BioPharma
  • Cirius Therapeutics
  • Enyo Pharma
  • Galectin Therapeutics
  • Galmed Pharmaceuticals Ltd.
  • Genfit
  • Gilead Sciences
  • Immuron
  • Intercept Pharmaceuticals
  • Inventiva Pharma
  • Madrigal Pharmaceuticals
  • MediciNova
  • Mitsubishi Tanabe Pharma
  • NGM Biopharmaceuticals
  • Novo Nordisk
  • Oramed Pharmaceuticals
  • TaiwanJ Pharmaceuticals
  • Terns Pharmaceuticals
  • And Many Others

 

Request for Sample Report: https://www.delveinsight.com/sample-request/nonalcoholic-steatohepatitis-nash-market

 

Some of Nonalcoholic Steatohepatitis (NASH) Therapies are:

  • Elafibranor (GFT505)
  • Obeticholic Acid (OCA, Ocaliva)
  • Selonsertib (SEL, Formerly GS-4997)
  • Cilofexor (GS-9674)
  • Firsocostat (GS-0976)
  • Aramchol
  • Pegbelfermin (BMS-986036)
  • IMM-124E
  • Belapectin (GR-MD-02)
  • MSDC-0602K
  • NGM282 (aldafermin)
  • JKB-122
  • Semaglutide
  • LJC242
  • LJN452 (Tropifexor)
  • MT-3995 (Apararenone)
  • MN-001 (Tipelukast)
  • Resmetirom (MGL-3196)
  • Lanifibranor (IVA33)
  • Namodenoson (CF102)
  • ORMD-0801
  • ASC40
  • TERN-101
  • EYP001
  • And Many Others

 

Table of Contents:

1. Key Insights

2. Executive Summary of Nonalcoholic Steatohepatitis

3. Competitive Intelligence Analysis for Nonalcoholic Steatohepatitis

4. Nonalcoholic Steatohepatitis: Market Overview at a Glance

5. Nonalcoholic Steatohepatitis: Disease Background and Overview

6. Patient Journey

7. Nonalcoholic Steatohepatitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Nonalcoholic Steatohepatitis Treatment and Management

8.2. Nonalcoholic Steatohepatitis Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Nonalcoholic Steatohepatitis Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Nonalcoholic Steatohepatitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Nonalcoholic Steatohepatitis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/nonalcoholic-steatohepatitis-nash-market

Categories